Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ: IRON )

22.06 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 22.06
Bid (Size) 1.330 (3)
Ask (Size) 45.01 (2)
Prev. Close 22.06
Today's Range 22.06 - 22.06
52wk Range 15.00 - 26.43
Shares Outstanding 5,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Heron Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Gainers Bird Global, Inc. (NYSE: BRDS) shares rose 58.7% to $0.2250 in pre-market trading after gaining more than 17% on Thursday. Bird announced plans to expand across Greater Toronto area this... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
 
Via Benzinga

Performance

YTD
+22.90%
+22.90%
1 Month
-11.76%
-11.76%
3 Month
+10.91%
+10.91%
6 Month
+10.91%
+10.91%
1 Year
+10.91%
+10.91%

More News

Read More
Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)
From Disc Medicine Inc
Via Globe NewsWire
Disc Medicine Opco Inc (NASDAQ: IRON) Investor Notice: Investigation over Possible Securities Laws Violations
Via SBWire
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2023
Via Benzinga
$2M Bet On PayPal? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Disc Medicine Initiates a Phase 1b/2 Clinical Study of DISC-0974 in Adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) and Anemia
From Disc Medicine Inc
Via Globe NewsWire
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
From Disc Medicine Inc
Via Globe NewsWire
Disc Medicine to Participate in SVB Securities Global Biopharma Conference
From Disc Medicine Inc
Via Globe NewsWire
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Via Talk Markets
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
From Disc Medicine Inc
Via Globe NewsWire
Stocks Stumbling Out Of 2023's Gate
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.